Related Experiment Video
Updated: Jul 13, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Optimizing platelet P2Y12 inhibition for patients undergoing PCI
Steven Steinhubl1, Matthew T Roe
1Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536, USA. srstei2@email.uky.edu
Cardiovascular Drug Reviews
|July 7, 2007
Summary
New antiplatelet agents like prasugrel, AZD6140, and cangrelor offer faster P2Y12 inhibition than clopidogrel for acute coronary syndromes. Ongoing trials will determine if these therapies improve outcomes in patients undergoing percutaneous coronary intervention (PCI).
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Dual antiplatelet therapy with aspirin and clopidogrel is recommended for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
- Optimal clopidogrel pretreatment timing and dosage for effective peri-PCI thrombotic event reduction remain challenging in clinical practice.
Purpose of the Study:
- To review novel P2Y12 receptor antagonists that provide faster and more consistent platelet inhibition compared to clopidogrel.
- To discuss the potential of prasugrel, AZD6140, and cangrelor to improve patient outcomes in PCI settings.
Main Methods:
- Review of clinical trial data and pharmacodynamic properties of new P2Y12 inhibitors.
- Comparison of efficacy and safety profiles with existing therapies like clopidogrel and abciximab.
Main Results:
- Prasugrel and AZD6140 demonstrate faster, potent, and consistent platelet inhibition with similar bleeding risks to clopidogrel in Phase II studies.
- Cangrelor shows rapid onset, reversible action, with comparable bleeding and outcomes to abciximab in preliminary data.
Conclusions:
- Newer P2Y12 antagonists offer potential advantages in achieving rapid and effective platelet inhibition for PCI patients.
- Results from ongoing Phase III trials are crucial to confirm improved clinical outcomes with these agents.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...